Yiyu Dong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4976953/publications.pdf

Version: 2024-02-01

23	1,257	471509 17	752698 20
papers	citations	h-index	g-index

23	23	23	2766
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. Molecular Cancer Therapeutics, 2022, 21, 382-394.	4.1	6
2	SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nature Cancer, 2022, 3, 188-202.	13.2	26
3	Mitonuclear genotype remodels the metabolic and microenvironmental landscape of HÃ¼rthle cell carcinoma. Science Advances, 2022, 8, .	10.3	15
4	A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. Biomaterials, 2021, 269, 120630.	11.4	27
5	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	3.3	21
6	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications, 2020, 11, 1975.	12.8	37
7	Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models. Cancer Research, 2019, 79, 242-250.	0.9	27
8	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. ELife, 2019, 8, .	6.0	31
9	Integrated Genomic Analysis of HÃ¼rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell, 2018, 34, 256-270.e5.	16.8	195
10	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nature Communications, 2017, 8, 15165.	12.8	61
11	The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Reports, 2017, 18, 2893-2906.	6.4	153
12	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nature Communications, 2017, 8, 16078.	12.8	135
13	Î”Np63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. Cell Reports, 2017, 21, 2926-2939.	6.4	61
14	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European Urology Focus, 2017, 3, 590-598.	3.1	31
15	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. JCO Precision Oncology, 2017, 1, 1-14.	3.0	9
16	Patient derived xenografts of upper tract urothelial carcinoma: A potential tool for personalized medicine.. Journal of Clinical Oncology, 2017, 35, 344-344.	1.6	0
17	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications, 2016, 7, 13131.	12.8	140
18	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. Journal of Clinical Investigation, 2016, 126, 3526-3540.	8.2	82

#	Article	IF	Citations
19	Comparing surgical tissue versus biopsy tissue in the development of a clear cell renal cell carcinoma xenograft model.. Journal of Clinical Oncology, 2016, 34, 519-519.	1.6	0
20	Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e16102-e16102.	1.6	0
21	Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. Cell Research, 2014, 24, 1354-1366.	12.0	29
22	PUMA and BIM Are Required for Oncogene Inactivationâ€“Induced Apoptosis. Science Signaling, 2013, 6, ra20.	3.6	107
23	Synthetic Lethality through Combined Notchâ€“Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer. Cancer Research, 2010, 70, 5465-5474.	0.9	64